Human CTLA-4 antibodies and their uses

Details for Australian Patent Application No. 2006201520 (hide)

Owner Medarex, Inc.

Inventors Halk, Edward L.; Keler, Tibor P.; Korman, Alan J.; Lonberg, Nils; Deo, Yashwant M.

Agent Spruson & Ferguson

Pub. Number AU-B-2006201520

Parent 784012

Filing date 11 April 2006

Wipo publication date 11 May 2006

Acceptance publication date 19 March 2009

International Classifications

A01K 67/027 (2006.01) Rearing or breeding animals, not otherwise provided for - New breeds of vertebrates

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 31/04 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 31/10 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 31/12 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 19/00 (2006.01) Hybrid peptides

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/02 (2006.01) Mutation or genetic engineering - Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12N 15/85 (2006.01) Mutation or genetic engineering - for animal cells

Event Publications

27 April 2006 Complete Application Filed

11 May 2006 Application Open to Public Inspection

  Published as AU-B-2006201520

19 March 2009 Application Accepted

  Published as AU-B-2006201520

16 July 2009 Standard Patent Sealed

19 January 2012 Extension of Term of Standard Patents

  Medarex, Inc. The earliest first regulatory approval date provided by the patentee 04 Jul 2011 For the goods YERVOY ipilimumab; WINGLORE ipilimumab Address for service in Australia: Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

7 June 2012 Extension granted

  Medarex, Inc. The earliest first regulatory approval date provided by the patentee 04 Jul 2011 For the goods YERVOY ipilimumab; WINGLORE ipilimumab Extension of Term of patent pursuant to Section 77 expires on 24 Aug 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006201521-Surgical fastener with predetermined resorption rate

2006201519-Suction brush of vacuum cleaner